ACM
CRDF icon

ACT Capital Management’s Cardiff Oncology CRDF Stock Holding History

ACT Capital Management’s Portfolio CRDF Stock Details CRDF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		$186K Hold
120,600
– – 0.26% 39
2022
Q2 		$265K Hold
120,600
– – 0.37% 38
2022
Q1 		$299K Buy
120,600
+18,100
+18% +$64K 0.32% 46
2021
Q4 		$616K Hold
102,500
– – 0.45% 42
2021
Q3 		$683K Hold
102,500
– – 0.35% 48
2021
Q2 		$682K Buy
+102,500
New +$869K 0.35% 57

Other funds holding CRDF

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

ACT Capital Management's CRDF Position: Q3 2022 in Review

ACT Capital Management held its Cardiff Oncology (CRDF) position steady in Q3 2022 at 120,600 shares worth $186K. The position accounts for 0.26% of the portfolio, ranked #39.

ACT Capital Management first reported a position in CRDF in Q2 2021 and has held it in 6 quarters since. The position peaked at $683K in Q3 2021. 58 funds tracked by Wall St. Rank hold CRDF as of Q3 2022.

  • ACT Capital Management held 120,600 shares of Cardiff Oncology worth $186K as of Q3 2022.
  • ACT Capital Management left its Cardiff Oncology share count unchanged in Q3 2022.
  • Cardiff Oncology made up 0.26% of ACT Capital Management's portfolio in Q3 2022, its #39 holding.
  • ACT Capital Management first reported a position in Cardiff Oncology in Q2 2021 and has held it in 6 quarters since.
  • ACT Capital Management's Cardiff Oncology position peaked at $683K in Q3 2021.
  • 58 funds tracked by Wall St. Rank held Cardiff Oncology as of Q3 2022.

Based on ACT Capital Management's 13F filing for Q3 2022, filed 3 Nov 2022.